Procuring organ donors as a health investment: How much should we be willing to spend?

Transplantation

Volumn 78, Issue 12, 2004, Pages 1704-1710

  Mendeloff, John ^a,b   Ko, Kilkon ^b   Roberts, Mark S ^a,c   Byrne, Margaret ^e   Dew, Mary Amanda ^a,c,d  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Donor; Economic analysis; Procurement; Quality adjusted life year

Indexed keywords

CADAVER DONOR; COST BENEFIT ANALYSIS; HEART; HUMAN; INVESTMENT; KIDNEY DONOR; LIVER GRAFT; ORGAN DONOR; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

CADAVER; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; LIFE EXPECTANCY; ORGAN TRANSPLANTATION; QUALITY-ADJUSTED LIFE YEARS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 11144329578     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000149787.97288.A2     Document Type: Review

References (26)

1. URREA; UNOS. 2002 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1992-2001 [Internet]. Rockville, MD: HHS/HRSA/OSP/DOT; 2003 [modified 2003 Feb 18; cited August 6, 2003]. Available from: http://www.optn.org/data/annualReport.asp.
2. Graham, JD. Evaluating the effectiveness of clinical and public health measures. Annu Rev Pub Hlth 1998; 19: 125.
3. Laupaucis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235.
4. O'Brien BJ, Buxton MJ, Ferguson BA. Measuring the effectiveness of heart transplant programmes: quality of life data and their relationship to survival analysis. J Chron Dis 1987; 40: 137S.
5. Institute of Medicine. Organ procurement and transplantation: assessing current policies and the potential impact of the DHHS final rule. Washington, DC: National Academy Press, 1999.
6. Gartner SH, Sevick MA, Kennan RJ, Chen GJ. Cost-utility of lung transplantation: a pilot study. J Heart Lung Transplant 1997; 16: 1129.
7. Gold MR, Siegel JE, Russell LB, Weinstein, MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
8. Weinstein MC, Stason WB. Hypertension: A Policy Perspective. Cambridge: Harvard University Press, 1976.
9. Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation - a prospective study. Transplantation 1992; 54: 656.
10. Hornberger JC, Best JH, Garrison LP Jr. Cost effectiveness of repeat medical procedures: kidney transplantation as an example. Med Decis Making 1997; 17: 363.
11. Pinson CW, Feurer ID, Payne JL, et al. Health-related quality of life after different types of solid organ transplantation. Ann Surg 2000; 232: 597.
12. Hauboldt RH. Cost Implications of Human Organ and Tissue Transplantations, An Update: 1999. Milliman & Robertson, Inc., unpublished report, 1999.
13. Hauboldt RH. Cost Implications of Human Organ and Tissue Transplantations, 1996. Milliman & Robertson, Inc., unpublished report, 1996.
14. Hertz MI, Taylor DO, Trulock EP, et al., The registry of the International Society for Heart and Lung Transplantation: nineteenth official report-2002. J Heart Lung Transplant 2002; 21: 950.
15. John R, Rajasinghe HA, Itescu S, et al. Factors affecting long-term survival (> 10 Years) after cardiac transplantation in the cyclosporine era. J Am Coll Cardiol 2001; 37: 189.
16. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232: 490.
17. Statistical Abstract of the United States, 2002 (Washington D.C.: Government Printing Office) Table 93.
18. Wolfe RA, Ashby VB, Milford EL, et al. Comparison on mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Eng J Med 1999; 341: 1725.
19. Toma H, Tanabe K, Tokumoto T, et al. Time-dependent risk factors influencing the long-term outcome in living renal allografts. Transplantation 2002; 72: 940.
20. Hariharan S, Jonson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988-1996. N Eng J Med 2000; 342: 605.
21. Garrison LP Jr. Assessing the Cost-Effectiveness of Development and Use of the Artificial Heart. In, Institute of Medicine, The Artificial Heart: Prototypes, Policies, and Patients. Washington D.C.: National Academy Press, 1991.
22. Cope JT, Kaza AK, Reade CC, et al. A cost comparison of heart transplantation versus alternative operations for cardiomyopathy. Ann Thorac Surg 2001; 72: 1298.
23. Bruns FJ, Seddon P, Saul M, Zeidel ML. The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. J Am Soc Nephrol 1998; 9: 884.
24. Wong LJ, McFall P, Wong LMF. The cost of dying of end-stage liver disease. Arch Intern Med 1997; 157: 1429.
25. Bell CM, Chapman RH, Stone PW, et al. An off-the-shelf list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 2001; 21: 288.
26. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163: 1637.0